USNA

Usana Health Sciences

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Consumer Defensive

industry

Packaged Foods

Exchange

NYSE

County of HQ

United States

Next Earnings Date

04/28/26

Business Summary

Usana Health Sciences operates in the consumer health and nutrition segment, generating revenue through the sale of packaged nutritional and personal care products. The model relies on brand-driven repeat purchases and distribution leverage rather than high technological differentiation. Cash generation comes from volume sales and maintaining tight control over manufacturing and distribution costs, which is critical given its 2.00% operating margin. The moat is primarily brand trust and customer loyalty within its niche, but with ROIC at 1.80%, the competitive advantage appears narrow and execution-dependent rather than structurally dominant.

 


Analyze USNA on TradingView

VALUATION

P/E

31.3

Market Cap ($M USD)

$334

Forward P/E

6.5

PEG

0.6

PRICE TO SALES

0.4

PRICE TO BOOK

0.6

EV / EBITDA

2.4

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$0.58

Next Year EPS Growth Estimate

$2.77

Next Year Revenue Growth Estimate

6.30%

Return on Equity (ROE)

2.00%

FREE CASH FLOW

Operating Margin

5.50%

Debt-to-Equity

0

Piotroski F-Score

7

Altman Z-Score

3.9

Return on Invested Capital (ROIC)

1.80%

Current Ratio

2.2

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze USNA on TradingView

Gainseekers Quantitative Analysis

Summary

At 31.3x trailing earnings with a collapse to 6.5x forward P/E, the market is signaling a dramatic earnings reset rather than stable growth. The PEG of 0.6 suggests theoretical undervaluation relative to growth, yet EPS is $2.4 while next year’s estimate is just $0.58, which implies compression, not acceleration. The balance sheet is not distressed — an Altman Z-Score of 3.9 and Current Ratio of 2.2 indicate financial stability — but profitability metrics like 2.00% operating margin and 1.80% ROIC are weak. This is not a high-quality compounder; it’s a statistically cheap stock facing earnings pressure where the valuation gap exists because the market doubts durability.

AI Exposure / Tech Reliance

As a Consumer Defensive company in Packaged Foods, AI exposure is indirect and operational rather than product-driven. The primary technological leverage would be in supply chain optimization, demand forecasting, and cost control, which could marginally improve its thin 2.00% operating margin. However, this is not a business model that meaningfully re-rates from AI adoption alone; resilience comes from staple demand, not technological disruption.

The Bull Case

A deep value or GARP investor could argue the setup is asymmetric. A Price/Sales of 0.4 and Price/Book of 0.6 imply the equity is trading below intrinsic asset value, while a Piotroski F-Score of 7 signals fundamentally sound operations relative to peers. The Forward P/E of 6.5 combined with a PEG of 0.6 suggests that if earnings stabilize even modestly above the $0.58 estimate, the stock is materially mispriced. Add an Altman Z-Score of 3.9 and a manageable Current Ratio of 2.2, and you have a balance sheet that is unlikely to force dilution or distress, giving patient investors time for normalization. Institutional ownership at $39.00 indicates some level of professional sponsorship, reinforcing the possibility that this is a cyclical trough rather than structural decay.

The Bear Case

The bear case is brutal. EPS collapsing from $2.4 to an estimated $0.58 while the stock still trades at 31.3x trailing earnings suggests the “cheap” forward multiple may simply reflect deteriorating profitability. Operating margin of 2.00% and ROIC of 1.80% are subpar, indicating weak competitive positioning and poor capital efficiency. Debt/Equity at 5.50% is not alarming in isolation, but combined with low returns on capital, it signals limited financial leverage to amplify shareholder value. The absence of a dividend (TTM Yield 0, Dividend Per Share -, Payout Ratio -) removes any income floor, and with a Mean Consensus Target Price of 3 against a Market Cap of $334, sentiment appears disconnected or uncertain. This is a low-margin business facing earnings compression — a dangerous mix.

Market Sentiment & Smart Money

Short Interest %

4.30%

Analyst Consensus

3

Average Analyst Price Target

$39.00

Institutional Ownership %

57.60%

1-Year Beta

1.24

Insider Buying % (6 Mo)

40.90%%

Distance to 52-Week High

47.30%

Distance to 52-Week Low

109.10%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.